We found that Sunitinib displayed more potent anti-tumor effects in mECK36 tumors than Imatinib, which correlated with the extent of inhibition of PDGFRA phosphorylation achieved by the drugs (Fig 6). Here, PDGFRA is linked to neoplasm.